Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6132766 | PACIRA PHARMS INC | Multivesicular liposomes with controlled release of encapsulated biologically active substances |
Nov, 2013
(10 years ago) | |
US8834921 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
US8182835 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
US9205052 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
US9585838 | PACIRA PHARMS INC | Production of multivesicular liposomes |
Dec, 2021
(2 years ago) | |
US11452691 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11357727 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11311486 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11278494 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11304904 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11819574 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11925706 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11426348 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11819575 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
US11931459 | PACIRA PHARMS INC | Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions |
Mar, 2042
(17 years from now) | |
US11918565 | PACIRA PHARMS INC | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
Feb, 2043
(18 years from now) |
Exparel is owned by Pacira Pharms Inc.
Exparel contains Bupivacaine.
Exparel has a total of 18 drug patents out of which 5 drug patents have expired.
Expired drug patents of Exparel are:
Exparel was authorised for market use on 28 October, 2011.
Exparel is available in injectable, liposomal;injection dosage forms.
Exparel can be used as method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia, method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia, single dose administration into the surgical site to produce postsurgical analgesia, a method of administering bupivacaine to produce regional analgesia via sciatic nerve block in the popliteal fossa in adults, a method of treating pain by administering bupivacaine via local infiltration in pediatric patients aged 6 to less than 12 years old undergoing cardiac surgery, method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, single-dose infiltration into the surgical site to produce postsurgical analgesia..
The generics of Exparel are possible to be released after 02 February, 2043.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Mar 22, 2024 |
New Indication(I-929) | Nov 09, 2026 |
New Indication(I-771) | Apr 06, 2021 |
New Product(NP) | Oct 28, 2014 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: Single-dose infiltration into the surgical site to produce postsurgical analgesia.; Single dose administration into the surgical site to produce postsurgical analgesia; Method of treating pain, for ex...
Dosage: INJECTABLE, LIPOSOMAL;INJECTION